These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26770041)

  • 1. Reappraisal of the Immunogenicity and Safety of Three Hepatitis A Vaccines in Adolescents.
    Yoon SH; Kim HW; Ahn JG; Kim IT; Kim JH; Kong KA; Kim KH
    J Korean Med Sci; 2016 Jan; 31(1):73-9. PubMed ID: 26770041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the immunogenicity and safety of 3 inactivated hepatitis A vaccines in Korean children aged 12 to 18 months: An open-label, randomized, prospective, multicenter study.
    Hong SS; Choi UY; Ma SH; Lee SY; Han SB; Kim KH; Kang JH; Kim JH
    Medicine (Baltimore); 2019 Feb; 98(6):e14364. PubMed ID: 30732169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.
    Dagan R; Amir J; Livni G; Greenberg D; Abu-Abed J; Guy L; Ashkenazi S; Foresner G; Tewald F; Schätzl HM; Hoffmann D; Ibanez R; Herzog C
    Pediatr Infect Dis J; 2007 Sep; 26(9):787-93. PubMed ID: 17721372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1-16 years.
    Abarca K; Ibáñez I; de la Fuente P; Cerda L; Bergeret J; Frösner G; Ibarra H
    Vaccine; 2011 Nov; 29(48):8855-62. PubMed ID: 21983354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of immunogenicity and persistence between inactivated hepatitis A vaccine Healive® and Havrix® among children: A 5-year follow-up study.
    Yu C; Song Y; Qi Y; Li C; Jiang Z; Li C; Zhang W; Wang L; Xia J
    Hum Vaccin Immunother; 2016 Oct; 12(10):2595-2602. PubMed ID: 27385349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing live attenuated and inactivated hepatitis A vaccines: an immunogenicity study after one single dose.
    Zheng H; Chen Y; Wang F; Gong X; Wu Z; Miao N; Zhang X; Li H; Chen C; Hou X; Cui F; Wang H
    Vaccine; 2011 Nov; 29(48):9098-103. PubMed ID: 21875638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interchangeability and tolerability of two inactivated hepatitis A vaccines in Chinese children.
    Zhang ZL; Zhu XJ; Wang X; Liang M; Sun J; Liu Y; Gao ZG; Wu JY; Dong XJ; Liu RK; Chen JT; Zhang YQ; Wang W; Zhang LP; Yin W
    Vaccine; 2012 Jun; 30(27):4028-33. PubMed ID: 22537990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine.
    Beck BR; Hatz CF; Loutan L; Steffen R
    J Travel Med; 2004; 11(4):201-6. PubMed ID: 15541221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single blind randomized phase 3 study to evaluate safety and immunogenicity of inactivated hepatitis A vaccine (HAPIBEV
    Thuluva S; Matur R; Tsa K; Gv SR
    Vaccine; 2021 Dec; 39(49):7166-7174. PubMed ID: 34763950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: a single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region, China.
    Liu XE; Wushouer F; Gou A; Kuerban M; Li X; Sun Y; Zhang J; Liu Y; Li J; Zhuang H
    Hum Vaccin Immunother; 2013 Jul; 9(7):1460-5. PubMed ID: 23571173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Serologic Follow-up of Children Vaccinated with a Pediatric Formulation of Virosomal Hepatitis A Vaccine Administered With Routine Childhood Vaccines at 12-15 Months of Age.
    Dagan R; Ashkenazi S; Livni G; Go O; Bagchi P; Sarnecki M
    Pediatr Infect Dis J; 2016 Jul; 35(7):e220-8. PubMed ID: 27093164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis A pediatric vaccines in toddlers, children and adolescents in China.
    Li RC; Li Y; Yi N; Huang L; Wan Z; Zhang Y; Rasuli A
    Pediatr Infect Dis J; 2013 Feb; 32(2):e77-81. PubMed ID: 23334341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunogenicity of a single dose of hepatitis A virus vaccines (Havrix® and Epaxal®) in Korean young adults.
    Lim J; Song YJ; Park WS; Sohn H; Lee MS; Shin DH; Kim CB; Kim H; Oh GJ; Ki M
    Yonsei Med J; 2014 Jan; 55(1):126-31. PubMed ID: 24339297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of immunogenicity of two hepatitis A vaccines--VAQTA and HAVRIX--in young adults.
    Ashur Y; Adler R; Rowe M; Shouval D
    Vaccine; 1999 May; 17(18):2290-6. PubMed ID: 10403597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.
    D'Acremont V; Herzog C; Genton B
    J Travel Med; 2006; 13(2):78-83. PubMed ID: 16553593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years.
    Van Der Wielen M; Vertruyen A; Froesner G; Ibáñez R; Hunt M; Herzog C; Van Damme P
    Pediatr Infect Dis J; 2007 Aug; 26(8):705-10. PubMed ID: 17848882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India.
    Jain H; Kumavat V; Singh T; Versteilen A; Sarnecki M
    Hum Vaccin Immunother; 2014; 10(7):2089-97. PubMed ID: 25424821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose.
    Zhang X; An J; Tu A; Liang X; Cui F; Zheng H; Tang Y; Liu J; Wang X; Zhang N; Li H
    Hum Vaccin Immunother; 2016 Sep; 12(9):2322-6. PubMed ID: 27494260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a virosomal hepatitis A vaccine in HIV-positive patients.
    Loutan L; Bovier P; Herzog C
    Vaccine; 2007 Aug; 25(34):6310-2. PubMed ID: 17640777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.